background & aim:  the aim of this study was to assess the bactericidal effect of three medicinal plant species, including thymus vulgaris, trachyspermum ammi, and mentha aquatica on erwinia carotovora growth. experimental: this research was done in a factorial to completely randomized design with three concentrations, and three replicates on nutrient agar culture medium. results &discu...

background: factor viii inhibitor is one of the most problems in the treatment of hemophilia. patients with hemophilia who have inhibitors are capable of severe hemorrhage and treatments of these patients are more expensive and more difficult than those patients without inhibitor. the aim of present study was to determine the prevalence of inhibitor and to assess the necessity of screening of t...

Introduction: Acquired hemophilia A is very rare autoimmune disorder caused by an autoantibody to factor VIII that interferes with its coagulant function. It may be associated a number of conditions such as lymphoproliferative disorders, drugs and solid malignancies. Hemarthrosis in clinical presentation was never reported cases induced penicillin. Case presentation: We report 65-year-old male,...

In recent years, advances in the pharmacological treatment of hemophilias A and B have mainly focused on the development of long-acting factor (F)VIII and FIX products. Alternative approaches not based on the replacement of the missing factor have also been explored, with the aim of producing therapeutic agents with reduced immunogenicity and yet equally effective in patients with or without in...

Inhibitors of the HER2/PI3K/AKT pathway are being developed, and shown promise in clinical trials for various types of cancers. However, development of drug resistance is a challenging problem for therapy. Elucidating various adaptive pathways leading to resistance or reduced sensitivity to drugs targeting the HER2/PI3K/AKT pathway may provide new insights into countering the resistance. Epider...

Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor) to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe, potentially life-threatening hemorrhage. Disease management focuses on controlling bleeding, primarily with the use of bypassing therapy and recombinant porcine FVIII, and permanently eradicating the autoantibody ...

Warfarin, an oral vitamin K antagonist, is used to prevent arterial and venous thromboembolism in patients suffering from a multitude of diseases. In 2004, 31 million warfarin prescriptions were dispensed in the United States. Warfarin inhibits the activation of the vitamin K-dependent clotting factors (Factors II, VII, IX, and X) and regulatory proteins (proteins C, S, and Z). It is one of the...

Fourteen individuals with severe hemophilia complicated by factor VIII inhibitors (1 to 132 Bethesda Units) were treated for 33 bleeding episodes with a new activated prothrombin complex concentrate, Anti-Inhibitor Coagulant Complex (Autoplex, Hyland, Glendale, Calif.). Excellent or good results were observed in 21 of 25 minor bleeding episodes treated, which included joint, soft tissue, and mu...

Downlo insulin-like growth factor-1 receptor (IGF1R) is emerging as a promising therapeutic target in human s. In the high-risk childhood sarcomas Ewing family tumor and rhabdomyosarcoma, IGF1R-blocking dies show impressive antitumor activity in some but not all patients, and acquired resistance is ed. Because tumor IGF1R mutations are not described, the basis of IGF1R inhibitor resistance s un...